Shares of Shockwave Medical Inc (NASDAQ:SWAV) have earned an average broker rating score of 3.00 (Hold) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three analysts have rated the stock with a hold rating.

Analysts have set a 12 month consensus price target of $45.67 for the company and are forecasting that the company will post ($0.55) EPS for the current quarter, according to Zacks. Zacks has also assigned Shockwave Medical an industry rank of 104 out of 256 based on the ratings given to related companies.

Several brokerages have recently weighed in on SWAV. Zacks Investment Research upgraded shares of DLH from a “sell” rating to a “hold” rating in a research note on Tuesday. Bank of America set a $10.00 target price on shares of HEXO and gave the company a “buy” rating in a research note on Thursday, June 13th. Morgan Stanley restated an “equal weight” rating on shares of KINGFISHER PLC/SH in a research note on Monday, April 1st. Wells Fargo & Co lifted their target price on shares of Stryker from $214.00 to $219.00 and gave the company an “outperform” rating in a research note on Monday, April 1st. Finally, Canaccord Genuity lifted their target price on shares of Shockwave Medical from $50.00 to $65.00 and gave the company a “positive” rating in a research note on Tuesday, June 18th.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC purchased a new position in shares of Shockwave Medical during the 1st quarter valued at $117,477,000. Gilder Gagnon Howe & Co. LLC purchased a new position in shares of Shockwave Medical during the 1st quarter valued at $44,601,000. Redmile Group LLC purchased a new position in shares of Shockwave Medical during the 1st quarter valued at $10,041,000. Advisory Services Network LLC purchased a new position in shares of Shockwave Medical during the 1st quarter valued at $26,000. Finally, Marshall Wace LLP purchased a new position in shares of Shockwave Medical during the 1st quarter valued at $1,016,000. Institutional investors own 45.60% of the company’s stock.

Shares of Shockwave Medical stock traded up $0.03 on Monday, hitting $50.83. 222,891 shares of the company’s stock were exchanged, compared to its average volume of 388,361. The firm has a 50-day moving average of $57.55. Shockwave Medical has a 1 year low of $24.58 and a 1 year high of $68.39. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.37 and a quick ratio of 9.89.

Shockwave Medical (NASDAQ:SWAV) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($1.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.85). The firm had revenue of $7.27 million for the quarter. As a group, research analysts anticipate that Shockwave Medical will post -2.74 EPS for the current year.

About Shockwave Medical

ShockWave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease.

Featured Story: Analyzing a company’s cash flow statement

Get a free copy of the Zacks research report on Shockwave Medical (SWAV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.